ArticleERJ open research2025
Effects of inhaled bronchodilators on dynamic lung mechanics during exercise in COPD: protocol for a randomised, placebo-controlled crossover trial.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Activity-related dyspnoea in moderate-severe COPD is centrally related to heightened wasted ventilation in the physiological dead space colliding with constraints to tidal expansion due to acute-on-chronic gas trapping. Both phenomena are ultimately related to small airway dysfunction. However, it remains unknown whether the positive effects of pharmacological deflation on exertional dyspnoea in COPD can be ascribed to improved small airway conductance, enhancing ventilation-perfusion matching and neuromechanical coupling. Main hypotheses: We postulate that inhaled bronchodilators will enhance small airway function at rest and during exercise, improving gas exchange efficiency, lung mechanics and exertional dyspnoea in hyperinflated patients with COPD. Methods: A double-blind, placebo-controlled study involving 25 symptomatic patients (modified Medical Research Council score ≥2) showing functional residual capacity >120% pred and/or >upper limit of normal will receive nebulised salbutamol sulphate (2.5 mg) plus ipratropium bromide (0.5 mg) or normal saline. On different days, patients will undergo a constant-load test at 75% peak to symptom limitation. Single- and multiple-breath N Implications: Confirmation of the study's hypotheses will shed new light on the mechanisms of dyspnoea improvement after inhaled bronchodilators in patients with COPD. Moreover, it will provide a novel integrative platform for assessing the effects of therapeutic approaches targeting their small airways.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.